Education
About Us
Working with TipRanks
Follow Us
MATTHEW D PERRY Insider Profile
4 Followers
MATTHEW D PERRY, Director at CTI BioPharma, holds 23.84K shares in XOMA Royalty Corporation (Ticker: XOMA), holds 0.00 shares in CTI BioPharma (Ticker: CTIC).
MATTHEW D PERRY CTI BioPharma (CTIC)Director
CTI BioPharma (CTIC)
Director
Not Ranked
MATTHEW D PERRY has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of MATTHEW D PERRY's holdings
Insider Roles
Director
Roles that MATTHEW D PERRY holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by MATTHEW D PERRY
MATTHEW D PERRY's Trading History
CTI BioPharma
Jun 26, 2023
―
Uninformative Sell
392.56K
$0.00
XOMA Royalty Corporation
May 23, 2025
Director
Uninformative Buy
―
$608.87K
List of latest transactions for each holding click on a transaction to see MATTHEW D PERRY's performance on stock
You May Also Like
MATTHEW D PERRY insider profile FAQ
What is the percentage of profitable transactions made by MATTHEW D PERRY?
The percentage of profitable transactions made by MATTHEW D PERRY is ―.
What is the average return per transaction made by MATTHEW D PERRY?
The average return per transaction made by MATTHEW D PERRY is ―.
What stocks does MATTHEW D PERRY hold?
MATTHEW D PERRY holds: CTIC, XOMA stocks.
What was MATTHEW D PERRY’s latest transaction?
MATTHEW D PERRY latest transaction was an Uninformative Buy of ―.
What was MATTHEW D PERRY's most profitable transaction?
MATTHEW D PERRY’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is MATTHEW D PERRY's role in CTI BioPharma?
MATTHEW D PERRY's role in CTI BioPharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.